Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage

Digestive Diseases and Sciences

Volumn 56, Issue 12, 2011, Pages 3648-3654

  Tomita, Kengo ^a,b   Teratani, Toshiaki ^a   Yokoyama, Hirokazu ^c   Suzuki, Takahiro ^a   Irie, Rie ^d   Ebinuma, Hirotoshi ^a   Saito, Hidetsugu ^c   Hokari, Ryota ^b   Miura, Soichiro ^b   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d KAWASAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Diagnosis; Immunoglobulin A; Liver fibrosis; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HYALURONIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOREACTIVE INSULIN; SERUM ALBUMIN; BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; BIOPSY; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84856269202     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1771-2     Document Type: Article

References (19)

1. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-728.
2. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86:285-300. (Pubitemid 47256910)
3. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol. 2007;23:193-198. (Pubitemid 46192974)
4. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liv Dis. 2001;21:17-26. (Pubitemid 32240483)
5. Adams LA, Lymp JF, Sauver JS, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121. (Pubitemid 41002048)
6. Van de Wiel A, Schuurman HJ, Kater L. Alcoholic liver disease: an IgA associated disorder. Scand J Gastroenterol. 1987;22:1025-1030. (Pubitemid 17156991)
7. Van de Wiel A, Van Hattum J, Schuurman HJ, Kater L. Immunoglobulin A in the diagnosis and alcoholic liver disease. Gastroenterology. 1988;94:457-462. (Pubitemid 18054785)
8. Gonzalez-Quintela A, Alende MR, Gamallo R, et al. Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease. Hepatogastroenterology. 2003;50:2121-2126. (Pubitemid 37468008)
9. Ishii H. Common pathogenic mechanisms in ASH and NASH. Hepatol Res. 2004;28:18-20. (Pubitemid 38145783)
10. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3-16. (Pubitemid 32240482)
11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116: 1413-1419. (Pubitemid 29258890)
12. Youden WJ. An index for rating diagnostic tests. Cancer. 1950;3:32-35.
13. Perkins NJ, Schisterman EF. The inconsistency of ''optimal'' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163: 670-675.
14. Yokoyama H, Nagata S, Moriya S, et al. Hepatic fibrosis produced in guinea pigs by chronic ethanol administration and immunization with acetaldehyde adducts. Hepatology. 1995;21: 1438-1442.
15. Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol. 2005;140:478-490. (Pubitemid 40813958)
16. Massonnet B, Delwail A, Ayrault JM, Chagnearu-Derrode C, Lecron JC, Silvain C. Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation. Clin Exp Immunol. 2009;158:115-124.
17. Rodriguez-Segade S, Camina MF, Carnero A, et al. High serum IgA concentrations in patients with diabetes mellitus: agewise distribution and relation to chronic complications. Clin Chem. 1996;42:1064-1067. (Pubitemid 26231412)
18. Gonzalez-Quintela A, Alende R, Gude F, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008;151: 42-50. (Pubitemid 350230994)
19. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005; 11:255-259. (Pubitemid 40125214)